Home  |  Contact

Cellosaurus TT2609-C02 (CVCL_2218)

[Text version]

Cell line name TT2609-C02
Synonyms TT2609-CO2
Accession CVCL_2218
Resource Identification Initiative To cite this cell line use: TT2609-C02 (RRID:CVCL_2218)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Doubling time: 21 hours (PubMed=11716037); ~60-80 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Mitochondrial genome sequenced.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Heterozygous for NRAS p.Gln61Arg (c.182A>G) (PubMed=23833040; PubMed=30737244).
Heterozygous for TERT c.228C>T (-124C>T); in promoter (PubMed=23833040; PubMed=30737244).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.11
Native American0.39
East Asian, North2.11
East Asian, South0
South Asian1.31
European, North62.71
European, South33.37
Disease Thyroid gland follicular carcinoma (NCIt: C8054)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_A594 ! TT2609-A02
CVCL_A595 ! TT2609-B02
Sex of cell Male
Age at sampling 57Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; PubMed=18713817; PubMed=30737244

Markers:
AmelogeninX,Y
CSF1PO12
D3S135816
D5S81812
D7S8208,10
D8S117912,13
D13S31711,13
D16S5399,11
D18S5114
D21S1128,30
FGA22,25
TH018,9.3
TPOX8,12
vWA17,18

Run an STR similarity search on this cell line
Publications

PubMed=11716037; DOI=10.1089/105072501753210966
Geldof A.A., Versteegh L.R.T., van Mourik J.C., Rooimans M.A., Arwert F., Hermsen M.A.J.A., Schadee-Eestermans I.L., van Dongen G.A., van der Valk P., van der Clement E.H.P., Lips P., Teule G.J.
Clonally related but phenotypically divergent human cancer cell lines derived from a single follicular thyroid cancer recurrence (TT2609).
Thyroid 11:909-917(2001)

PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=25675381; DOI=10.1210/jc.2014-2764
von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J., Tun H.W., Smallridge R.C., Copland J.A.
Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
J. Clin. Endocrinol. Metab. 100:E697-E709(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=29066502; DOI=10.1530/ERC-17-0288
Corver W.E., Demmers J., Oosting J., Sahraeian S., Boot A., Ruano D., Wezel T.V., Morreau H.
ROS-induced near-homozygous genomes in thyroid cancer.
Endocr. Relat. Cancer 25:83-97(2018)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31443247; DOI=10.3390/cancers11081185
Aydemirli M.D., Corver W., Beuk R., Roepman P., Solleveld-Westerink N., van Wezel T., Kapiteijn E., Morreau H.
Targeted treatment options of recurrent radioactive iodine refractory Hurthle cell cancer.
Cancers (Basel) 11:1185.1-1185.16(2019)

Cross-references
Cell line collections DSMZ; ACC-510
Cell line databases/resources CCLE; TT2609C02_THYROID
Cell_Model_Passport; SIDM00418
Cosmic-CLP; 1240223
DepMap; ACH-000716
LINCS_LDP; LCL-1681
Biological sample resources BioSample; SAMN03473513
BioSample; SAMN10989561
Chemistry resources GDSC; 1240223
PharmacoDB; TT2609C02_1607_2019
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM887712
GEO; GSM888805
GEO; GSM1670550
Other Wikidata; Q54973225
Polymorphism and mutation databases Cosmic; 1995660
Cosmic; 2054095
LiGeA; CCLE_442
Entry history
Entry creation04-Apr-2012
Last entry updated19-Dec-2019
Version number22